Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price1,611.00 GBp
Fair value805.50
Ethical score76.6/100
RatingAVOID
Our investment reviews on this name
2026-10-02Read Distribution1,611.00+0.0% to today
2026-08-31Read Markup1,463.00+10.1% to today ✓
2026-07-02Read Accumulation1,463.00+10.1% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Hikma Pharmaceuticals holds its Distribution at $1,611.00. The statistical read favours the sellers, held for 21 days.
As held on the ledger · 2026-09-21
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 21 days
Price at the screen
$1,611.00
Valuation
1,202.24 trailing · 878.64 forward price to earnings
Values screen
PASS· score 76.6
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
28.28%
Below 33%
Interest-bearing debt is just 28.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
3.83%
Below 33%
Cash held in interest-bearing accounts and securities is 3.8% of assets, under the one-third limit.
Pass
Receivables
17.58%
Below 49%
Money owed to the company is 17.6% of assets, under the 49% limit.
Pass
Revenue purity
2.72%
Below 5%
Only 2.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Hikma Pharmaceuticals clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 28%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades above our $805.50 fair value estimate, 8.50% revenue growth.
Fair value range in GBp, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. The price runs 50.0% above the base estimate.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 878.6x forward earnings, the price already runs ahead of the business. It trades 50% above our $805.50 fair value, so you would be buying at a premium, not a discount.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HIK.L trades on LSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 10.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (11 analysts) rates it buy, with a mean price target of $1896.
2026-08-31Markup · changed$1,463.00+0.0%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (11 analysts) rates it buy, with a mean price target of $1896.
2026-08-01Accumulation$1,463.00+0.0%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (11 analysts) rates it buy, with a mean price target of $1896.
2026-07-18Accumulation$1,463.00+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 30%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (11 analysts) rates it buy, with a mean price target of $1896.
2026-07-03Accumulation$1,463.00+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Accumulation$1,463.00Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.